fenofibric acid

RN given refers to parent cpd without isomeric designation; structure

Also Known As:

2-(4-(4'-chlorophenoxy)phenoxy)propionic acid; HCG 004; fenofibric acid potassium salt; fenofibric acid sodium salt; fenofibric acid, (R)-isomer; 2-(4-(4-chlorophenoxy)phenoxy)propanoic acid

Networked: 86 relevant articles (10 outcomes, 27 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kelly, Maureen T: 20 articles (06/2014 - 12/2008)
2.	Setze, Carolyn M: 19 articles (08/2013 - 12/2008)
3.	Stolzenbach, James C: 15 articles (06/2014 - 12/2008)
4.	Jones, Peter H: 10 articles (11/2012 - 12/2008)
5.	Sleep, Darryl J: 10 articles (03/2011 - 12/2008)
6.	Ballantyne, Christie M: 9 articles (06/2014 - 02/2009)
7.	Carlson, Dawn M: 7 articles (06/2014 - 01/2010)
8.	Davidson, Michael H: 7 articles (06/2014 - 04/2009)
9.	Lele, Aditya: 7 articles (06/2014 - 04/2009)
10.	Williams, Laura A: 6 articles (06/2014 - 01/2010)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 04/01/2007 - "This method is suitable for quantification of fenofibric acid for clinical pharmacokinetic studies in patients with dyslipidemia." 01/01/2009 - "Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia." 10/01/2010 - "The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes." 04/01/2012 - "Fenofibric acid in combination with low- to moderate-dose statins is an effective and safe option in the treatment of mixed dyslipidemia, although the long-term effects on cardiovascular risk reduction need to be explored further." 12/01/2008 - "To evaluate the long-term safety and efficacy of fenofibric acid combined with statins in adults with mixed dyslipidemia. "
2.	Type 2 Diabetes Mellitus (MODY) 10/01/2010 - "The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes." 01/01/2010 - "Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials." 02/01/2015 - "The aim of the study was to evaluate the potential effect of fenofibric acid (FA), the active metabolite of fenofibrate, in preventing retinal neurodegeneration in an experimental mouse model of type 2 diabetes. " 02/01/2011 - "Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus." 01/01/2010 - "Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy. "
3.	Neoplasms (Cancer) 04/01/2015 - "Although some pharmacokinetic studies were performed in the past, data are still needed about the detailed subcellular and tissue distribution of fenofibrate (FF) and its active metabolite, fenofibric acid (FA), especially in respect to the treatment of intracranial tumors. " 07/01/2019 - "However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARα agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death. " 01/01/2021 - "Finally, the co-treatment of Paclitaxel and fenofibric acid (fibrates active metabolite) was tested on different cancer cell lines, no decrease in the antitumoral effect of paclitaxel was observed. " 12/29/2020 - "Finally, co-administration of paclitaxel and the active metabolite of fenofibrate (fenofibric acid) did not interfere with the suppression of tumor cell growth or clonogenicity by paclitaxel in ovarian and breast cancer cell lines. "
4.	Hypertriglyceridemia 01/01/2014 - "echinulata NCIM 691, Rhizopus stolonifer NCIM 880, Mucor rouxi MTCC 386, Trichothecium roseum NCIM 1147 were screened for their potential to biotransform anti-hyperlipidemia and anti-hypertriglyceridemia drug, fenofibrate to fenofibric acid, the active metabolite and other mammalian metabolites. " 01/01/2010 - "Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study." 02/01/2011 - "The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 09/05/1983 - "The fact that fenofibric acid, a hypolipidemic drug, can also inhibit growth promoting activity of PDGF suggests that this drug can be effective on the prevention of atherosclerosis and cardiovascular diseases by at least two independent mechanisms." 08/01/2012 - "Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. "

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Lipids
3.	Rosuvastatin Calcium (Crestor)
4.	Triglycerides (Triacylglycerol)
5.	HDL Cholesterol
6.	oxidized low density lipoprotein
7.	LDL Cholesterol
8.	Atorvastatin (Lipitor)
9.	Fenofibrate (CiL)
10.	Simvastatin (Zocor)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Renal Dialysis (Hemodialysis)